Abstract: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
March 17, 2015
Assignee:
The Regents of the University of Michigan
Inventors:
James R. Baker, Jr., Xue-min Cheng, Abraham F. L. Van Der Spek, Baohua Mark Huang, Thommey P. Thomas
Abstract: The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.
Abstract: Storage stable polyhydroxylated aromatic ether adducts of polyalkylene oxide are described. Reactive compositions are formed by combining an ether adduct with an aldehyde, optionally further adding a phenolic-aldehyde prepolymer. The reactive compositions are cured by removing water, by acidification, or both. The cured compositions sorb solvated compounds from environments containing water. The cured compositions are also useful for pre-loading with compounds that are subsequently released at a controlled rate into environments containing water.
Abstract: Pheromone compositions based on a combination of squalene, linoleic acid and 1-docosanol are described. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors.
Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.
Abstract: A functional TFE copolymer fine powder is described, wherein the TFE copolymer is a polymer of TFE and at least one functional comonomer, and wherein the TFE copolymer has functional groups that are pendant to the polymer chain. The functional TFE copolymer fine powder resin is paste extrudable and expandable. Methods for making the functional TFE copolymer are also described. The expanded functional TFE copolymer material may be post-reacted after expansion.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
January 20, 2015
Assignee:
W. L. Gore & Associates, Inc.
Inventors:
Ping Xu, Jack J. Hegenbarth, Xin Kang Chen, Rachel Radspinner, Paul D. Drumheller, William B. Johnson, Wen K. Liu
Abstract: There is disclosed an organopolysiloxane represented by the following general formula (1). (each R1 independently represents a group selected from an alkyl group having 1 to 30 carbon atoms, a fluorine-substituted alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, and an aralkyl group having 6 to 30 carbon atoms; Y represents a polyvalent alcohol compound residue; M represents any of a hydrogen atom, an alkaline metal atom, an ammonium ion, and an alkylammonium ion; and reference character m represents an integer of 0 to 300.) There can be an organopolysiloxane capable of providing a cosmetic having excellent emulsion stability, excellent powder-dispersion stability if powders are contained therein, and excellent skin affinity and cosmetic durability, due to a novel organopolysiloxane having a specific structure containing a nonionic hydrophilic group and an anionic hydrophilic group of a carboxylic acid structure; and a cosmetic containing it.
Abstract: The invention relates to an oligomeric lactic acid composition comprising one or more oligomers of lactic acid or a pharmaceutical composition comprising an oligomeric lactic acid composition for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment.
Type:
Grant
Filed:
March 28, 2013
Date of Patent:
December 16, 2014
Assignee:
Laccure AB
Inventors:
Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
Abstract: A expandable porous body constituted by a compressed apatite/collagen composite, which expands by water absorption, and a method for producing an expandable, porous apatite/collagen composite, which expands by water absorption, comprising the steps of freezing a porous apatite/collagen composite impregnated with a liquid in a compressed state, and drying it.
Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.
Type:
Grant
Filed:
December 20, 2010
Date of Patent:
December 2, 2014
Assignee:
Interface Biologics, Inc.
Inventors:
Roseita Esfand, J. Paul Santerre, Sylvia Tjahyadi, Bernadette Ilagan
Abstract: A dietary supplement formulation for reducing the risk of coronary heart disease or stroke, and in which there is provided a plurality of vitamins and minerals that together represent a minimum daily requirement thereof. Added to this composition is aspirin and plant sterols.
Abstract: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
November 18, 2014
Assignee:
The Regents of The University of Michigan
Inventors:
James R. Baker, Jr., Xue-min Cheng, Abraham F. L. Van Der Spek, Baohua Mark Huang, Thommey P. Thomas
Abstract: The present invention relates to bleaching composition for keratin fibres, especially human hair, comprising at least one compound with bleaching and/or highlighting effect and a calcium salt. Further object of the present invention is the use of at least one calcium salt in a bleaching and/or highlighting composition for keratin fibres, especially for human hair, comprising at least one compound with bleaching and/or highlighting effect for preventing temperature increase going above 40° C., preferably above 45° C. and more preferably above 50° C. in a period of at least 60 min after mixing water free bleaching and/or highlighting composition and oxidizing lotion.
Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.
Abstract: A functional TFE copolymer fine powder is described, wherein the TFE copolymer is a polymer of TFE and at least one functional comonomer, and wherein the TFE copolymer has functional groups that are pendant to the polymer chain. The functional TFE copolymer fine powder resin is paste extrudable and expandable. Methods for making the functional TFE copolymer are also described. The expanded functional TFE copolymer material may be post-reacted after expansion.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
October 7, 2014
Assignee:
W.L. Gore & Associates, Inc.
Inventors:
Ping Xu, Jack J. Hegenbarth, Rachel Radspinner, Paul D. Drumheller, William B. Johnson, Wen Liu, Xin Kang Chen
Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent.
Abstract: A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold.
Abstract: This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled.
Type:
Grant
Filed:
November 5, 2012
Date of Patent:
August 19, 2014
Assignee:
Dow Corning Corporation
Inventors:
John Bernard Horstman, Randall Gene Schmidt, Steven Swier